Insider Selling: Cardlytics (NASDAQ:CDLX) CFO Sells 8,493 Shares of Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 8,493 shares of the stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $2.27, for a total transaction of $19,279.11. Following the completion of the sale, the chief financial officer owned 195,417 shares of the company’s stock, valued at approximately $443,596.59. The trade was a 4.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Cardlytics Price Performance

CDLX stock opened at $2.37 on Friday. Cardlytics, Inc. has a 12-month low of $0.85 and a 12-month high of $5.24. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 2.87. The company has a market cap of $126.18 million, a price-to-earnings ratio of -0.65 and a beta of 1.45. The company has a 50 day moving average of $1.57 and a two-hundred day moving average of $1.73.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Millennium Management LLC bought a new position in Cardlytics in the fourth quarter valued at approximately $535,000. ProShare Advisors LLC bought a new position in Cardlytics in the fourth quarter valued at approximately $43,000. Two Sigma Investments LP lifted its stake in Cardlytics by 12.5% in the fourth quarter. Two Sigma Investments LP now owns 94,901 shares of the company’s stock valued at $352,000 after buying an additional 10,508 shares in the last quarter. Two Sigma Advisers LP lifted its stake in Cardlytics by 44.1% in the fourth quarter. Two Sigma Advisers LP now owns 36,900 shares of the company’s stock valued at $137,000 after buying an additional 11,300 shares in the last quarter. Finally, Lane Generational LLC bought a new position in Cardlytics in the first quarter valued at approximately $1,109,000. Institutional investors and hedge funds own 68.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Cardlytics in a research note on Saturday, September 27th. Evercore ISI dropped their price target on shares of Cardlytics from $3.00 to $2.00 and set an “in-line” rating on the stock in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $2.25.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.